

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (previously presented) A non-naturally occurring enterokinase-cleavable fusion protein comprising a polypeptide comprising the formula:  
(1)  $Z_1\text{-Xaa}_1\text{-Xaa}_2\text{-Xaa}_3\text{-Xaa}_4\text{-Asp-Arg-Xaa}_5\text{-Z}_2$  (SEQ ID NO:1),  
wherein  
(a)  $Z_1$  is a ligand recognition sequence;  
(b)  $\text{Xaa}_1\text{-Xaa}_2\text{-Xaa}_3\text{-Xaa}_4\text{-Asp-Arg}$  is an enterokinase recognition sequence, in which  
 $\text{Xaa}_1$  is Ala, Asp, Glu, Phe, Gly, Ile, Asn, Ser, or Val;  
 $\text{Xaa}_2$  is Ala, Asp, Glu, His, Ile, Leu, Met, Gln or Ser;  
 $\text{Xaa}_3$  is Asp, Glu, Phe, His, Ile, Met, Asn, Pro, Val, or Trp; and  
 $\text{Xaa}_4$ - is Ala, Asp, Glu, or Thr; and  
(c)  $\text{Xaa}_5\text{-Z}_2$  is a protein of interest, in which  $\text{Xaa}_5$  can be any amino acid and  $Z_2$  is a polypeptide of at least one amino acid.

2. (previously presented) The fusion protein of claim 1, wherein  
 $\text{Xaa}_1$  is Asp,  
 $\text{Xaa}_2$  is Ile,  
 $\text{Xaa}_3$  is Asn,  
 $\text{Xaa}_4$ -is Asp, and  
 $\text{Xaa}_5$ -is Met, Thr, Ser, Ala, Asp, Leu, Phe, Asn, Trp, Ile, Gln, Glu, His, Val, Gly or Tyr.

3. (canceled)

4. (previously presented) The fusion protein of claim 1, wherein the ligand recognition sequence  $Z_1$  is a streptavidin binding domain.

5. (original) The fusion protein of claim 4, wherein the streptavidin binding domain is selected from the sequences: His-Pro-Gln-Phe (SEQ ID NO:6), Cys-His-Pro-Gln-Phe-Cys (SEQ ID NO:5), Cys-His-Pro-Gln-Phe-Cys-Ser-Trp-Arg (SEQ ID NO:7), Trp-His-Pro-Gln-Phe-Ser-Ser (SEQ ID NO:210), Pro-Cys-His-Pro-Gln-Phe-Pro-Arg-Cys-Tyr (SEQ ID NO:211), and tandemly arranged combinations and repeats thereof.

6. – 49. (canceled)

50. (currently amended) The fusion protein according to claim 1, wherein said ligand recognition sequence  $Z_1$  ~~is selected from the group consisting of: streptavidin, avidin, an antibody, a peptide antigen recognized by the antibody;~~ comprises the Myc-tag, the Flag peptide, the KT3 epitope peptide, an  $\alpha$ -tubulin epitope peptide, ~~a polyhistidine tag,~~ a chitin binding domain, maltose binding protein (MBP), ~~and or~~ or a T7 gene 10-protein peptide tag.

51. (Previously presented) The fusion protein according to claim 1, wherein incubation of said polypeptide (SEQ ID NO:1) with enterokinase yields the protein of interest  $Xaa_5-Z_2$ .

52. (new) The fusion protein of claim 1 wherein said ligand recognition sequence  $Z_1$  comprises streptavidin or avidin.

53. (new) The fusion protein of claim 1 wherein said ligand recognition sequence  $Z_1$  comprises an antibody.

54. (new) The fusion protein of claim 1 wherein said ligand recognition sequence Z<sub>1</sub> comprises a peptide antigen recognized by an antibody.

55. (new) The fusion protein of claim 1 wherein said ligand recognition sequence Z<sub>1</sub> comprises a polyhistidine tag.

56. (new) The fusion protein of claim 1 further comprising a signal sequence.

57. (new) The fusion protein of claim 1 wherein Xaa<sub>1</sub> is Asp.

58. (new) The fusion protein of claim 1 wherein Xaa<sub>2</sub> is Ile.

59. (new) The fusion protein of claim 1 wherein Xaa<sub>3</sub> is Asn.

60. (new) The fusion protein of claim 1 wherein Xaa<sub>4</sub> is Asp.

61. (new) The fusion protein of claim 1 wherein Xaa<sub>5</sub> is Arg, Lys, Cys, Met, Thr, Ser, Ala, Asp, Leu, Phe, Asn, Trp, Ile, Gln, Glu, His, Val, Gly or Tyr.

62. (new) The fusion protein of claim 1 wherein Xaa<sub>5</sub> is Arg, Lys, Met, Thr, Ser, Ala, Asp, Leu, Phe, Asn, Trp, Ile, Gln, Glu, His, Val, Gly or Tyr.

63. (new) The fusion protein of claim 1 wherein Xaa<sub>5</sub> is Arg, Met, Thr, Ser, Ala, Asp, Leu, Phe, Asn, Trp, Ile, Gln, Glu, His, Val, Gly or Tyr.

64. (new) The fusion protein of claim 1 wherein Xaa<sub>5</sub> is Met, Thr, Ser, Ala, Asp, Leu, Phe, Asn, Trp, Ile, Gln, Glu, His, Val, Gly or Tyr.

65. (new) The fusion protein of claim 1, wherein Xaa<sub>1</sub> is Asp, Xaa<sub>2</sub> is Ile, Xaa<sub>3</sub> is Asn, and Xaa<sub>4</sub>-is Asp.

66. (new) The fusion protein of claim 1, wherein Xaa<sub>1</sub> is Ser, Xaa<sub>2</sub> is Leu, Xaa<sub>3</sub> is Asp, and Xaa<sub>4</sub>-is Asp.

67. (new) The fusion protein of claim 1, wherein Xaa<sub>1</sub> is Phe, Xaa<sub>2</sub> is Ser, Xaa<sub>3</sub> is Glu, and Xaa<sub>4</sub>-is Glu.

68. (new) The fusion protein of claim 1, wherein Xaa<sub>1</sub> is Ile, Xaa<sub>2</sub> is Glu, Xaa<sub>3</sub> is Asp, and Xaa<sub>4</sub>-is Glu.

69. (new) The fusion protein of claim 1, wherein Xaa<sub>1</sub> is Ala, Xaa<sub>2</sub> is Ala, Xaa<sub>3</sub> is Val, and Xaa<sub>4</sub>-is Glu.

70. (new) The fusion protein of claim 1 that is isolated.

71. (new) The fusion protein of claim 2, 4, 5, 50, 51, 52, 53, 54, 55, or 56 that is isolated.

72. (new) The fusion protein of claim 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, or 59 that is isolated.